Gabriele Gugliotta
YOU?
Author Swipe
View article: Ultrasound-guided core needle biopsy of nodular lesions of the spleen in hematology clinical practice
Ultrasound-guided core needle biopsy of nodular lesions of the spleen in hematology clinical practice Open
Background Solid splenic lesions may be the expression of a lymphoproliferative disease spreading to the spleen or appear as the only manifestation of possible neoplastic diseases, mainly hematologic malignancies. Therefore, biopsy is of u…
View article: 348 | LONG‐TERM EFFICACY OF IMMUNE CHECKPOINT INHIBITORS FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL B‐CELL LYMPHOMA: A RETROSPECTIVE, MONOCENTRIC STUDY FROM BOLOGNA, ITALY
348 | LONG‐TERM EFFICACY OF IMMUNE CHECKPOINT INHIBITORS FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL B‐CELL LYMPHOMA: A RETROSPECTIVE, MONOCENTRIC STUDY FROM BOLOGNA, ITALY Open
View article: SARS-CoV-2 infection does not affect the outcome of patients with relapsed/refractory large B-cell lymphoma treated with CAR T-cell therapy
SARS-CoV-2 infection does not affect the outcome of patients with relapsed/refractory large B-cell lymphoma treated with CAR T-cell therapy Open
View article: 511 | ACCURACY OF PERCUTANEOUS ULTRASOUND‐GUIDED NEEDLE BIOPSY OF ABDOMINAL LYMPH‐NODES FOR THE DIAGNOSIS OF MALIGNANT DISEASE
511 | ACCURACY OF PERCUTANEOUS ULTRASOUND‐GUIDED NEEDLE BIOPSY OF ABDOMINAL LYMPH‐NODES FOR THE DIAGNOSIS OF MALIGNANT DISEASE Open
View article: Therapeutic Vaccinations with p210 Peptides in Imatinib-Treated Chronic Myeloid Leukemia Patients: 10 Years Follow-Up of GIMEMA CML0206 and SI0207 Studies
Therapeutic Vaccinations with p210 Peptides in Imatinib-Treated Chronic Myeloid Leukemia Patients: 10 Years Follow-Up of GIMEMA CML0206 and SI0207 Studies Open
Background: We previously showed that peptides encompassing the unique b3a2 or b2a2 breakpoint amino-acid sequence of oncogenic p210 induced peptide-specific T-cell responses in chronic myeloid leukemia (CML) patients. Methods: From 2007 t…
View article: SETD2 loss of function is a recurrent event in advanced‐phase chronic myeloid leukemia and contributes to genomic instability
SETD2 loss of function is a recurrent event in advanced‐phase chronic myeloid leukemia and contributes to genomic instability Open
The SETD2 tumour suppressor encodes a histone methyltransferase that specifically trimethylates histone H3 on lysine 36 (H3K36me3), a key histone mark implicated in the maintenance of genomic integrity among other functions. We found that …
View article: Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practice
Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practice Open
View article: Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world study
Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world study Open
No abstract available
View article: Efficacy and Safety of Frontline Single‐Agent Rituximab in Extranodal Marginal Zone Lymphoma
Efficacy and Safety of Frontline Single‐Agent Rituximab in Extranodal Marginal Zone Lymphoma Open
First‐line therapy for patients with extranodal marginal zone lymphoma (EMZL) is not well established, except for eradication therapy for Helicobacter pylori in early gastric MZL. Various regimens, for example, locoregional treatment and s…
View article: The Treatment of Burkitt Lymphoma With the Berlin-Frankfurt-Münster Protocol With Rituximab and Consolidative Autologous Transplantation
The Treatment of Burkitt Lymphoma With the Berlin-Frankfurt-Münster Protocol With Rituximab and Consolidative Autologous Transplantation Open
Introduction Intensive treatment approaches are required for adult patients with Burkitt lymphoma (BL), although an univocal standard of care still does not exist. The use of frontline autologous stem cells transplantation (ASCT) is debate…
View article: Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia
Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia Open
No abstract available
View article: The treatment of Burkitt lymphoma with the Berlin‐Frankfurt‐Münster protocol with rituximab and autologous transplantation
The treatment of Burkitt lymphoma with the Berlin‐Frankfurt‐Münster protocol with rituximab and autologous transplantation Open
Introduction: Burkitt lymphoma (BL) is a highly aggressive B-cell lymphoma; because of its fast growing rate, it often represents a clinical emergency. Intensive treatment approaches are required for adult BL, although a univocal standard …
View article: BEGEV as salvage regimen in first setting for relapsed/refractory classical Hodgkin lymphoma
BEGEV as salvage regimen in first setting for relapsed/refractory classical Hodgkin lymphoma Open
Introduction: One of the most critical issues in the management of Hodgkin lymphoma (HL) patients who resulted as primary relapsed or refractory is to obtain a minimal disease status before autologous stem cell transplantation (ASCT) with …
View article: Role of autologous stem cell transplantation or salvage chemotherapy in relapsed/refractory classical Hodgkin lymphoma patients after immune checkpoint inhibitors
Role of autologous stem cell transplantation or salvage chemotherapy in relapsed/refractory classical Hodgkin lymphoma patients after immune checkpoint inhibitors Open
Introduction: Programmed death-1 (PD1) blockade is an efficient and safe therapeutic option in patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). However, many patients progress or lose the response to immune checkpo…
View article: Single‐agent rituximab as an effective salvage therapy in pre‐treated hairy cell leukemia
Single‐agent rituximab as an effective salvage therapy in pre‐treated hairy cell leukemia Open
Introduction: Hairy cell leukemia (HCL) patients usually experience multiple disease relapses during the course of their disease. The CD20 antigen is highly expressed on the surface of hairy cells. Single-agent rituximab can be a suitable …
View article: Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials
Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials Open
View article: IL-18 and VEGF-A trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemia
IL-18 and VEGF-A trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemia Open
Chronic Myeloid Leukemia (CML) is a hematologic malignancy associated to an unregulated growth of myeloid cells in Bone Marrow (BM) and Peripheral Blood (PB), characterized by the BCR-ABL1 translocation. Given the known cytokine impairment…
View article: Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors Open
In chronic myeloid leukemia (CML), Aurora kinase A and Polo like kinase 1 (PLK1), two serine-threonine kinases involved in the maintenance of genomic stability by preserving a functional G2/M checkpoint, have been implicated in BCR::ABL1-i…
View article: S152: SETD2/H3K36ME3 DEFICIENCY SUSTAINS GENOMIC INSTABILITY AND ENHANCES CLONOGENIC POTENTIAL OF CHRONIC MYELOID LEUKEMIA (CML) PROGENITORS
S152: SETD2/H3K36ME3 DEFICIENCY SUSTAINS GENOMIC INSTABILITY AND ENHANCES CLONOGENIC POTENTIAL OF CHRONIC MYELOID LEUKEMIA (CML) PROGENITORS Open
Background: Genomic instability is a hallmark of chronic myeloid leukemia (CML) cells since the chronic phase (CP) of the disease and results in BCR-ABL1 mutations and/or additional genetic and genomic aberrations that may drive resistance…
View article: P698: BOSUTINIB DOSE OPTIMIZATION IN THE SECOND-LINE TREATMENT OF ELDERLY CML PATIENTS: EXTENDED 3-YEAR FOLLOW-UP AND FINAL RESULTS OF THE BEST STUDY
P698: BOSUTINIB DOSE OPTIMIZATION IN THE SECOND-LINE TREATMENT OF ELDERLY CML PATIENTS: EXTENDED 3-YEAR FOLLOW-UP AND FINAL RESULTS OF THE BEST STUDY Open
Background: The median age of CML patients requiring a second-line treatment is older than 60 years and many of these patients have relevant comorbidities. Bosutinib (BOS) is a second-generation TKI, with similar efficacy to dasatinib and …
View article: Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study Open
We report the final analysis, with a 10-year follow-up, of the phase II study GIMEMA CML 0307 (NCT 00481052), which enrolled 73 adult patients (median age 51 years; range, 18-83) with newly diagnosed chronic-phase chronic myeloid leukemia …
View article: Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia Open
In this provocative commentary, we consider several questions posed by the late chronic myeloid leukaemia (CML) expert Prof. Michele Baccarani, which he challenged us to address after his death. He noted only a small proportion of people w…
View article: Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools
Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools Open
View article: COVID‐19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report
COVID‐19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report Open
Summary Limited information is available on the impact of the COVID‐19 pandemic on the management of chronic myeloid leukaemia (CML). The Campus CML network collected retrospective information on 8 665 CML patients followed at 46 centres t…
View article: Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study
Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study Open
These findings, although evaluated in a limited and selected cohort of patients, suggest that DAS might be effective in older patients (aged >75 years) affected by CP-CML with acceptable toxicity.
View article: Polo-like Kinase-1, Aurora Kinase A and Wee1 Kinase Are Novel Therapeutic Targets in Chronic Myeloid Leukemia
Polo-like Kinase-1, Aurora Kinase A and Wee1 Kinase Are Novel Therapeutic Targets in Chronic Myeloid Leukemia Open
BackgroundIn chronic myeloid leukemia (CML), Aurora kinase A and Polo like kinase 1 (Plk1), two serine-threonine kinases involved in the maintenance of a functional G2/M checkpoint, may cooperate with the constitutive tyrosine-kinase (TK) …
View article: Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib Open
View article: Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study
Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study Open
A limited amount of data has been published in chronic-phase chronic myeloid leukemia (CP-CML) patients aged >75 years treated frontline with second-generation tyrosine kinase inhibitors. To address this issue in a clinical ‘real-life’ set…
View article: Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey Open
View article: Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study Open